IL157119A0 - Prevention of diabetes by administration of gnrh antagonists - Google Patents
Prevention of diabetes by administration of gnrh antagonistsInfo
- Publication number
- IL157119A0 IL157119A0 IL15711901A IL15711901A IL157119A0 IL 157119 A0 IL157119 A0 IL 157119A0 IL 15711901 A IL15711901 A IL 15711901A IL 15711901 A IL15711901 A IL 15711901A IL 157119 A0 IL157119 A0 IL 157119A0
- Authority
- IL
- Israel
- Prior art keywords
- diabetes
- administration
- prevention
- gnrh antagonists
- gnrh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/771,434 US20020103131A1 (en) | 2001-01-26 | 2001-01-26 | Prevention of diabetes by administration of GnRH antagonists |
PCT/US2001/041603 WO2002058715A1 (en) | 2001-01-26 | 2001-08-06 | Prevention of diabetes by administration of gnrh antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157119A0 true IL157119A0 (en) | 2004-02-08 |
Family
ID=25091800
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15711901A IL157119A0 (en) | 2001-01-26 | 2001-08-06 | Prevention of diabetes by administration of gnrh antagonists |
IL157119A IL157119A (en) | 2001-01-26 | 2003-07-27 | Use of GNRH antagonists to make medicine to delay type 1 diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL157119A IL157119A (en) | 2001-01-26 | 2003-07-27 | Use of GNRH antagonists to make medicine to delay type 1 diabetes |
Country Status (12)
Country | Link |
---|---|
US (2) | US20020103131A1 (xx) |
EP (1) | EP1359931A4 (xx) |
JP (1) | JP2004521114A (xx) |
KR (1) | KR100857628B1 (xx) |
CN (1) | CN1267148C (xx) |
AU (1) | AU2002243197B2 (xx) |
CA (1) | CA2435877C (xx) |
HK (1) | HK1065700A1 (xx) |
IL (2) | IL157119A0 (xx) |
NO (1) | NO20033373L (xx) |
WO (1) | WO2002058715A1 (xx) |
ZA (1) | ZA200305803B (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
AU2003300351A1 (en) * | 2002-12-19 | 2004-07-14 | Praecis Pharmaceuticals, Inc. | Methods of enhancing immune system function in a subject |
EP2526950A1 (en) * | 2006-04-07 | 2012-11-28 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
RU2010113977A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae |
WO2009043455A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
CA2723541A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
CN107569456A (zh) | 2012-06-01 | 2018-01-12 | 辉凌公司 | 制造地加瑞克 |
CA2958939A1 (en) | 2014-08-26 | 2016-03-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
EP3250191B1 (en) | 2015-01-29 | 2024-01-17 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5434136A (en) * | 1990-12-14 | 1995-07-18 | Mathias; John R. | Treatment of motility disorders with a GNRH analog |
US5480969A (en) * | 1992-09-15 | 1996-01-02 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
US5624895A (en) * | 1994-02-18 | 1997-04-29 | Georgetown University Medical Center | Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration |
TR200003048T2 (tr) * | 1998-02-23 | 2000-12-21 | Neurocrine Biosciences, Inc. | İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. |
-
2001
- 2001-01-26 US US09/771,434 patent/US20020103131A1/en not_active Abandoned
- 2001-08-06 JP JP2002559049A patent/JP2004521114A/ja active Pending
- 2001-08-06 KR KR1020037009926A patent/KR100857628B1/ko not_active IP Right Cessation
- 2001-08-06 CA CA2435877A patent/CA2435877C/en not_active Expired - Fee Related
- 2001-08-06 AU AU2002243197A patent/AU2002243197B2/en not_active Ceased
- 2001-08-06 CN CNB018229786A patent/CN1267148C/zh not_active Expired - Fee Related
- 2001-08-06 WO PCT/US2001/041603 patent/WO2002058715A1/en active Application Filing
- 2001-08-06 EP EP01989075A patent/EP1359931A4/en not_active Withdrawn
- 2001-08-06 IL IL15711901A patent/IL157119A0/xx unknown
-
2002
- 2002-07-12 US US10/193,862 patent/US6875843B2/en not_active Expired - Fee Related
-
2003
- 2003-07-27 IL IL157119A patent/IL157119A/en not_active IP Right Cessation
- 2003-07-28 ZA ZA200305803A patent/ZA200305803B/xx unknown
- 2003-07-28 NO NO20033373A patent/NO20033373L/no not_active Application Discontinuation
-
2004
- 2004-10-28 HK HK04108461A patent/HK1065700A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002058715A1 (en) | 2002-08-01 |
CN1492766A (zh) | 2004-04-28 |
US20020103131A1 (en) | 2002-08-01 |
US20030045475A1 (en) | 2003-03-06 |
CA2435877C (en) | 2011-02-22 |
NO20033373L (no) | 2003-09-25 |
HK1065700A1 (en) | 2005-03-04 |
CN1267148C (zh) | 2006-08-02 |
US6875843B2 (en) | 2005-04-05 |
EP1359931A1 (en) | 2003-11-12 |
ZA200305803B (en) | 2004-07-28 |
JP2004521114A (ja) | 2004-07-15 |
IL157119A (en) | 2012-01-31 |
EP1359931A4 (en) | 2008-08-13 |
AU2002243197B2 (en) | 2006-09-14 |
KR20040004514A (ko) | 2004-01-13 |
CA2435877A1 (en) | 2002-08-01 |
NO20033373D0 (no) | 2003-07-28 |
KR100857628B1 (ko) | 2008-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157119A0 (en) | Prevention of diabetes by administration of gnrh antagonists | |
GB0126151D0 (en) | Administration of medicaments by vaporisation | |
GB0117618D0 (en) | Pharmaceutical dosage form | |
MXPA03010007A (es) | USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA. | |
IL161214A0 (en) | Compositions for delivery of drug combinations | |
GB0108228D0 (en) | Medicament dispenser | |
GB0108213D0 (en) | Medicament dispenser | |
GB0123941D0 (en) | Medicament dispenser | |
GB0108215D0 (en) | Medicament dispenser | |
GB0108208D0 (en) | Medicament dispenser | |
GB0130284D0 (en) | Medicament dispenser | |
GB0130857D0 (en) | Medicament dispenser | |
GB0125134D0 (en) | Medicament dispenser | |
GB0111597D0 (en) | Pharmaceutical compositions | |
GB0117619D0 (en) | Pharmaceutical dosage form | |
HK1069526A1 (en) | Anti-influenza drugs | |
MXPA03005980A (es) | Composiciones para administracion nasal de insulina. | |
GB0104752D0 (en) | Pharmaceutical compositions | |
AU2002249304A8 (en) | Novel human gnrh receptor | |
GB0108923D0 (en) | Administration of beneficial substances | |
TW492328U (en) | Improved structure of syringe | |
GB0110485D0 (en) | Medicament dispenser | |
AU2002325516A1 (en) | Gnrh agonist combination drugs | |
GB0122399D0 (en) | Dosage forms | |
GB0121677D0 (en) | Dosage |